C
CRINETICS PHARMACEUTICALS INC
NASDAQ: CRNX (Crinetics Pharmaceuticals, Inc.)
Last update: 1 hour ago34.20
0.10 (0.29%)
| Previous Close | 34.10 |
| Open | 34.27 |
| Volume | 841,791 |
| Avg. Volume (3M) | 967,208 |
| Market Cap | 3,220,818,944 |
| Price / Sales | 2.17 |
| Price / Book | 2.71 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Operating Margin (TTM) | -30,860.11% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | -43.60% |
| Total Debt/Equity (MRQ) | 4.05% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -261.57 M |
| Levered Free Cash Flow (TTM) | -155.77 M |
| Return on Assets (TTM) | -20.13% |
| Return on Equity (TTM) | -30.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
2.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.25 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 112.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ecor1 Capital, Llc | 30 Jun 2025 | 4,288,120 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2025 | 2,343,553 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 86.00 (JMP Securities, 151.46%) | Buy |
| Median | 83.50 (144.15%) | |
| Low | 81.00 (HC Wainwright & Co., 136.84%) | Buy |
| Average | 83.50 (144.15%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 28.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 11 Aug 2025 | 86.00 (151.46%) | Buy | 27.38 |
| HC Wainwright & Co. | 27 Jun 2025 | 81.00 (136.84%) | Buy | 29.96 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |